Athena Athena

X
[{"orgOrder":0,"company":"ECP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECP Pharma Developing Innovative Drug Products For Neurological and Central Nervous System Diseases","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECP Pharma\u2019s Path Forward Clearer After FDA\u2019s Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by ECP Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ECP-101, unique drug therapy involving cannabinoids and psychedelics will be used to promote a quick recovery and overcome the long term consequences often seen with mTBI.

            Lead Product(s): ECP-101

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ECP-101

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ECP-101, unique drug therapy involving cannabinoids and psychedelics will be used to promote a quick recovery and overcome the long term consequences often seen with mTBI.

            Lead Product(s): ECP-101

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ECP-101

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY